| Dr Corinne M Self, MD | |
|
1846 E Innovation Park Dr, Oro Valley, AZ 85755-1963 | |
| (520) 829-9987 | |
| (833) 989-2161 |
| Full Name | Dr Corinne M Self |
|---|---|
| Gender | Female |
| Speciality | Geriatric Medicine |
| Experience | 13 Years |
| Location | 1846 E Innovation Park Dr, Oro Valley, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255629762 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R72765 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Desert Harmony Hospice Of Tucson | Tucson, AZ | Hospice |
| Casa De La Luz Hospice | Tucson, AZ | Hospice |
| Oro Valley Hospital | Oro valley, AZ | Hospital |
| Northwest Medical Center | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elderhealth Pllc | 5890105985 | 2 |
News Archive
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on halting the progression of type 1 diabetes.
Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.
Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 9 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on halting the progression of type 1 diabetes.
Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.
Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 9 days ago
| Entity Name | Elderhealth Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336746692 PECOS PAC ID: 5890105985 Enrollment ID: O20201030000965 |
News Archive
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on halting the progression of type 1 diabetes.
Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.
Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Corinne M Self, MD 1846 E Innovation Park Dr, Oro Valley, AZ 85755-1963 Ph: () - | Dr Corinne M Self, MD 1846 E Innovation Park Dr, Oro Valley, AZ 85755-1963 Ph: (520) 829-9987 |
News Archive
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation on halting the progression of type 1 diabetes.
Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.
Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.
Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.
› Verified 9 days ago
Dr. Clarence James Hindman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 75 E Beekeeper Trail, Oro Valley, AZ 85755 Phone: 520-991-6863 Fax: 520-797-6724 | |
John D Dougherty Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 E. Vuelta Caminata Del Rio, Oro Valley, AZ 85737 Phone: 520-547-5688 Fax: 520-547-4661 | |
Benjamin Sarsah, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1824 E Innovation Park Dr, Oro Valley, AZ 85755 Phone: 520-623-2642 Fax: 520-623-6162 | |
Corbin Ballam, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1521 E Tangerine Rd Ste 315, Oro Valley, AZ 85755 Phone: 520-901-6350 | |
Dr. Robert William Irwin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1834 E Innovation Park Dr, Oro Valley, AZ 85755 Phone: 520-825-9656 Fax: 520-818-2525 | |
Paul R Butler, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1521 E Tangerine Rd, Suite #123, Oro Valley, AZ 85755 Phone: 520-901-6336 Fax: 520-901-6337 |